First-of-its-Kind gene therapy injected into spine to fight Alzheimer's
Disease control
Completed
This early-stage study tested the safety of a new gene therapy, LX1001, for people with Alzheimer's disease who carry a specific genetic risk factor (two copies of the APOE4 gene). The therapy was injected into the spinal fluid of 15 participants over a year to see if it was safe…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC